Lupin shares in focus after USFDA approval for modafinil tablets
Lupin said the US Food and Drug Administration approved its modafinil tablets, aimed at improving wakefulness in adult patients with excessive sleepiness. The stock will remain in focus on September 7.
Lupin shares will remain in focus on September 7 after the company received US Food and Drug Administration approval for tablets that improve wakefulness in adult patients with excessive sleepiness. The company said it has received approval from the United States Food and Drug Administration for its abbreviated application.